Science & Technology Partners L.P. Makes New $7.76 Million Investment in Glaukos Co. (NYSE:GKOS)

Science & Technology Partners L.P. bought a new stake in Glaukos Co. (NYSE:GKOS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 51,750 shares of the medical instruments supplier's stock, valued at approximately $7,759,000. Glaukos accounts for 2.4% of Science & Technology Partners L.P.'s investment portfolio, making the stock its 16th biggest holding. Science & Technology Partners L.P. owned approximately 0.09% of Glaukos as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Harbor Capital Advisors Inc. bought a new stake in shares of Glaukos during the 4th quarter valued at $3,679,000. Sanctuary Advisors LLC bought a new stake in Glaukos during the third quarter worth about $258,000. Rhumbline Advisers grew its holdings in Glaukos by 0.3% in the fourth quarter. Rhumbline Advisers now owns 141,790 shares of the medical instruments supplier's stock worth $21,260,000 after purchasing an additional 403 shares during the period. IFP Advisors Inc bought a new position in shares of Glaukos during the fourth quarter valued at approximately $43,000. Finally, US Bancorp DE lifted its holdings in shares of Glaukos by 8.3% during the fourth quarter. US Bancorp DE now owns 6,099 shares of the medical instruments supplier's stock valued at $914,000 after purchasing an additional 470 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors.

Insider Transactions at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the firm's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tomas Navratil sold 3,416 shares of the company's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company's stock.

Glaukos Stock Performance

GKOS stock traded down $0.52 during midday trading on Tuesday, reaching $93.29. 232,354 shares of the company's stock traded hands, compared to its average volume of 879,129. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 52-week low of $77.91 and a 52-week high of $163.71. The stock has a market cap of $5.33 billion, a P/E ratio of -32.51 and a beta of 0.88. The stock's 50-day moving average is $101.01 and its 200 day moving average is $129.91.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The company had revenue of $105.50 million during the quarter, compared to analysts' expectations of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. As a group, analysts anticipate that Glaukos Co. will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on GKOS. Needham & Company LLC boosted their target price on Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Mizuho reduced their price objective on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research note on Wednesday, April 16th. Wells Fargo & Company upped their target price on shares of Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Stifel Nicolaus raised their price target on shares of Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research report on Tuesday, December 31st. Finally, Truist Financial cut their target price on Glaukos from $185.00 to $140.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $156.17.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.